ABSTRACT
This study was designed to investigate the effects of combination of ezetimibe, simvastatin and omega-3-fatty acids on lipoproteins in patients with mixed dyslipidemia. Among the 102 patients were screened 98 who met the inclusion and exclusion criteria after 6 weeks on a strict diet therapy were grouped into four treatment groups (2 patients left out in between). The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499 mg per 100 ml) and a total cholesterol level more than 200 mg per 100 ml. Present study was conducted on dyslipidemic patients receiving ezetimibe (10 mg) alone, simvastatin (20 mg) alone, omega-3-fatty acids (4 g) alone and combination of simvastatin (20 mg) and ezetimibe (10 mg) and omega-3-fattyacids (4g) daily for 12weeks. After 12 weeks treatment (Tc, LDL)was found decreased, Tg level reduced significantly and HDL level increased in the combination therapy (Simvastatin, ezetimibe and omega-3-fattyacids) than monotherapy. From the result it is concluded that combination therapy of these three may be considered as an optimal treatment option for patients with mixed dyslipidemia.
ABSTRACT
This study was designed to investigate the effects of combination of ezetimibe and simvastatin on lipoproteins in patients with mixed dyslipidemia. Among the 482 patients screened 465 who met the inclusion criteria after 6weeks on a strict diet therapy were grouped into three treatment groups. The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499 mg per 100ml) and a total cholesterol level more than 200mg per 100ml. Retrospective study was conducted on dyslipidemic patients receiving ezetimibe (10mg) alone, simvastatin (20mg) alone, and combination of simvastatin (20mg) and ezetimibe (10mg) daily for 24weeks. After 24 weeks treatment,(Tc, Tg, LDL)was found significantly decreased and HDL level increased in the combination therapy (Simvastatin and ezetimibe) than monotherapy. From the result it is concluded that combination therapy may be considered as an optimal treatment option for patients with mixed dyslipidemia.
ABSTRACT
The conventional dosage forms stay in the stomach for 0.5-2 hours and passes to small intestine and where it gets absorbed within 3-6 hours. Therefore difficult to adjust release retardation and stomach retention of drug for longer period of time. The present research work was attempted to formulate and evaluate the floating tablet with biphasic release of metoprolol succinate. Metoprolol succinate bioahesive gastric drug delivery system was prepared using bioadhesive polymer PEO, Hydrophylic polymer (Carbopol 71G, HPMC E15, Methacrylic acid, Pectin, Carragenan and Guargum) and gas forming agent Sodium bicarbonate. Metoprolol succinate bioahesive gastric drug delivery system was proved to be attained the effective plasma concentration higher than the Marketed formulation. This is due to retaining metoprolol succinate in the stomach (Where it absorbed more) by means of floating and bioadhesive property of the polymer. Metoprolol succinate bioahesive gastric drug delivery system using PEO and HPMC E15 polymers could be effective sustained release formulation.
ABSTRACT
The aim of the present research work is to develop bilayer tablet dosage form containing combination of immediate and sustained release layer prepared using Glibenclamide and Metformin Hydrochloride respectively for the treatment of Type-11 diabetes mellitus. Immediate release of glibenclamide granules was prepared with different superdisintegrant. Metformin hydrochloride sustained release granules were prepared by non-aqueous wet granulation technique. Both pre-compression and post compression parameters were analyzed for all the tablets. Bilayer tablets was formulated using croscarmellose sodium for immediate release of Glibenclamide showed 99.94% of release in 30 minutes and using hydrophilic HPMC K100 and hydrophobic Ethyl cellulose in the ratio of 1:1 released 99.90% of Metformin hydrochloride for the period of 13 hours. From this research work it is evident that the formulated bilayer tablet has ability to release the Glibenclamide immediately and Metformin hydrochloride for longer period of time, which can be used for treatment of type11 diabetes mellitus compared to Marketed formulation.
ABSTRACT
Merremia emarginata Burm. F (Convolvulaceae) is a perennial, much branched herb (creeper). It is found widely distributed all over the India, specially in damp places in upper gangetic plain, Gujarat, Bihar, West Bengal, Western‐ Ghats, ascending up to 900m in the hills, Goa, Karnataka in India, Ceylon and Tropical Africa. Merremia emarginata is also known as Ipomoea reniformis chois. It is reported to have many important medicinal properties. In the Indigenous system of Medicine, Ipomoea reniformis has been claimed to be useful for cough, headache, neuralgia, rheumatism, diuretic, inflammation, troubles of nose, fever due to enlargement of liver and also for treating cancer. The present study was designed to evaluate the invitro anticancer activity of Merremia emarginata Burm.F. The different solvent fraction of whole plant Merremia emarginata Burm.F was subjected for MTT assay. The ethylacetate fraction of whole plant was found to be cytotoxic against human cervical carcinoma Hela cell lines and human breast carcinoma MCF cell lines. The IC50 value of ethylacetate fraction was 51.57μg/ml against Hela cell lines and 39.6μg/ml against MCF-7 cell lines. Significant results were observed thereby justifying the use of plant in the traditional system of medicine.